ArticleCancer medicine2018
Excessive risk of second primary cancers in young-onset colorectal cancer survivors.
Article in Cancer medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Pooled it
- Risk of extracolonic second primary cancers following a primary colorectal cancer: a systematic review and meta-analysis.International journal of colorectal disease · 2022Pooled it
- Second Primary Malignancies in Gastrointestinal Cancer Survivors: Epidemiology, Risk Factors, and Future Prediction Models.Cancers · 2026Review
- Subsequent malignant neoplasm among cancer survivors in the United States.Journal of cancer survivorship : research and practice · 2026Article
- Prognostic factors for 5 year relapse-free survivors following curative resection for stage II/III colorectal cancer.Surgery today · 2026Article
- Subsequent primary cancer risks for non-hereditary colorectal cancer survivors.EClinicalMedicine · 2026Article
- Sequential changes in conditional survival of patients following surgical resection of colorectal cancer and indicators for follow-up beyond 5 years.International journal of clinical oncology · 2026Article
- Melanoma and Colorectal Cancer as Second Primary Cancers: A Scoping Review of Their Association and the Underlying Biological, Lifestyle, and Genetic Factors.Journal of gastrointestinal cancer · 2025Article
- Do cancer survivors have an increased risk of developing subsequent cancer? A population-based study.Journal of translational medicine · 2025Article
- Prognosis and clinicopathological features of patients with early-onset and late-onset colorectal cancer with second primary malignancies.Journal of gastroenterology and hepatology · 2025Article
- Synchronous Primary Gallbladder and Colon Adenocarcinoma: A Case Report and Systematic Literature Review.Cureus · 2024Article
- Obesity and early-onset colorectal cancer risk: emerging clinical evidence and biological mechanisms.Frontiers in oncology · 2024Review
- Characteristics and classification of first primary cancer patients with second primary cancer: a population-based cohort study.Clinical and experimental medicine · 2023Article
- Colorectal cancer in adolescent and young adults: epidemiology in Japan and narrative review.Journal of gastrointestinal oncology · 2023Review
- Incidence and risk outcomes of second primary malignancy of patients with post-operative colorectal cancer.International journal of colorectal disease · 2023Article
- Risk of colon cancer-related death in people who had cancer in the past.International journal of colorectal disease · 2022Article
- Patients with Early-Onset Colorectal Cancer Have an Increased Risk of Second Primary Malignancy.Digestive diseases and sciences · 2022Article
- Disparities in Recommendations for Colorectal Cancer Screening Among Average-Risk Individuals: An Ecobiosocial Approach.Risk management and healthcare policy · 2022Review
- Survival outcomes in prostate cancer patients with a prior cancer.Translational andrology and urology · 2021Article
- Clinical characteristics and overall survival nomogram of second primary malignancies after prostate cancer, a SEER population-based study.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With an increasing trend of patients with young-onset colorectal cancer (CRC), risks of second primary cancers (SPCs) among them become a concerning issue. We aimed to define the detailed risk and site-distributed patterns of SPCs in young CRC individuals (age ≤50). A population-based cohort were identified from the Surveillance, Epidemiology, and End Results database between 1973 and 2013. Standardized incidence ratios (SIRs) and absolute excess risk (AER) were calculated to assess the risk for SPCs compared with the general population. A total of 44,106 patients, including 3245 (7.4%) the young and 40,861 (92.6%) the old, developed 50,679 secondary malignancies subsequently. With increased age, the risk of secondary cancers gradually decreased. A significant 44% excess risk of SPCs was observed in the young (SIR = 1.44, AER = 34.23), while a slightly increased risk was noted in the old (SIR = 1.02, AER = 4.29). For young survivors, the small intestine (SIR = 8.49), bile ducts (SIR = 3.77), corpus, and uterus (SIR = 2.45) were the most common sites of SPCs. Significantly, excess SIRs in the young were persisted regardless of other factors. For the young, secondary cancer-related deaths were responsible for 51.2% of overall deaths and secondary stomach, liver and bile, pancreas cancers were top three causes. An excessive risk of SPCs existed in young CRC survivors, and this trend was consistent among different subgroups. We hope our findings may inform future targeted screening strategies among young-onset CRC survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.